Cytokinetics, Incorporated
CYTK
$43.27
-$0.61-1.39%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 912.38% | 22.49% | -71.28% | -81.90% | -14.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 912.38% | 22.49% | -71.28% | -81.90% | -14.56% |
| Cost of Revenue | 10.18% | 2.52% | -4.32% | 2.71% | 13.27% |
| Gross Profit | 7.93% | -2.43% | 3.62% | -7.92% | -14.02% |
| SG&A Expenses | 41.31% | 41.24% | 27.95% | -8.39% | -18.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.82% | 15.18% | 6.11% | -1.56% | 0.08% |
| Operating Income | -9.12% | -15.16% | -6.66% | -1.42% | -0.31% |
| Income Before Tax | -9.59% | -24.05% | -11.41% | -3.32% | 0.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.59% | -24.05% | -11.41% | -3.32% | 0.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.59% | -24.05% | -11.41% | -3.32% | 0.35% |
| EBIT | -9.12% | -15.16% | -6.66% | -1.42% | -0.31% |
| EBITDA | -12.86% | -14.93% | -6.30% | -1.04% | 3.42% |
| EPS Basic | 8.06% | -1.27% | 2.34% | 3.54% | 4.76% |
| Normalized Basic EPS | 8.06% | -1.26% | 2.33% | 3.54% | 4.76% |
| EPS Diluted | 8.06% | -1.27% | 2.34% | 3.54% | 4.76% |
| Normalized Diluted EPS | 8.06% | -1.26% | 2.33% | 3.54% | 4.76% |
| Average Basic Shares Outstanding | 19.19% | 22.50% | 14.08% | 7.10% | 4.63% |
| Average Diluted Shares Outstanding | 19.19% | 22.50% | 14.08% | 7.10% | 4.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
